186 related articles for article (PubMed ID: 10071687)
1. P53 overexpression and proliferative potential in malignant meningiomas.
Nagashima G; Aoyagi M; Yamamoto M; Yamamoto S; Wakimoto H; Ohno K; Yamamoto K; Hirakawa K
Acta Neurochir (Wien); 1999; 141(1):53-61; discussion 60-1. PubMed ID: 10071687
[TBL] [Abstract][Full Text] [Related]
2. Expression of p53, MDM2 protein and Ki-67 antigen in recurrent meningiomas.
Ohkoudo M; Sawa H; Hara M; Saruta K; Aiso T; Ohki R; Yamamoto H; Maemura E; Shiina Y; Fujii M; Saito I
J Neurooncol; 1998 May; 38(1):41-9. PubMed ID: 9540056
[TBL] [Abstract][Full Text] [Related]
3. Immunohistochemical study of Ki-67 (MIB-1), p53 protein, p21WAF1, and p27KIP1 expression in benign, atypical, and anaplastic meningiomas.
Amatya VJ; Takeshima Y; Sugiyama K; Kurisu K; Nishisaka T; Fukuhara T; Inai K
Hum Pathol; 2001 Sep; 32(9):970-5. PubMed ID: 11567227
[TBL] [Abstract][Full Text] [Related]
4. Prognostic significance of MIB-1, p53, and bcl-2 immunoreactivity in meningiomas.
Karamitopoulou E; Perentes E; Tolnay M; Probst A
Hum Pathol; 1998 Feb; 29(2):140-5. PubMed ID: 9490273
[TBL] [Abstract][Full Text] [Related]
5. Correlation between histological grade, MIB-1, p53, and recurrence in 69 completely resected primary intracranial meningiomas with a 6 year mean follow-up.
Lanzafame S; Torrisi A; Barbagallo G; Emmanuele C; Alberio N; Albanese V
Pathol Res Pract; 2000; 196(7):483-8. PubMed ID: 10926326
[TBL] [Abstract][Full Text] [Related]
6. Immunohistochemical expression of SPARC is correlated with recurrence, survival and malignant potential in meningiomas.
Bozkurt SU; Ayan E; Bolukbasi F; Elmaci I; Pamir N; Sav A
APMIS; 2009 Sep; 117(9):651-9. PubMed ID: 19703125
[TBL] [Abstract][Full Text] [Related]
7. Accumulation of wild-type p53 in meningiomas.
Ellison DW; Lunec J; Gallagher PJ; Steart PV; Jaros E; Gatter KC
Neuropathol Appl Neurobiol; 1995 Apr; 21(2):136-42. PubMed ID: 7609844
[TBL] [Abstract][Full Text] [Related]
8. Tumor grade-related NDRG2 gene expression in primary and recurrent intracranial meningiomas.
Skiriute D; Tamasauskas S; Asmoniene V; Saferis V; Skauminas K; Deltuva V; Tamasauskas A
J Neurooncol; 2011 Mar; 102(1):89-94. PubMed ID: 20607352
[TBL] [Abstract][Full Text] [Related]
9. Clinicopathological variables, immunophenotype, chromosome 1p36 loss and tumour recurrence of 247 meningiomas grade I and II.
Ruiz J; Martínez A; Hernández S; Zimman H; Ferrer M; Fernández C; Sáez M; López-Asenjo JA; Sanz-Ortega J
Histol Histopathol; 2010 Mar; 25(3):341-9. PubMed ID: 20054806
[TBL] [Abstract][Full Text] [Related]
10. p53 and PCNA expression in benign, atypical and malignant meningiomas.
Ahmed R; Soomro IN; Aziz SA; Hasan SH
J Pak Med Assoc; 1999 Oct; 49(10):241-3. PubMed ID: 10647228
[TBL] [Abstract][Full Text] [Related]
11. [Expression of HER2/neu in meningiomas: an immunohistochemistry and fluorescence in situ hybridization study].
Wang CL; Mei JH; Wang SS; Xu S; Xu LL; Xiong YF
Zhonghua Bing Li Xue Za Zhi; 2010 Mar; 39(3):156-60. PubMed ID: 20450760
[TBL] [Abstract][Full Text] [Related]
12. [P53 protein expression and proliferative potential in non-recurrent and recurrent meningiomas].
Miyagami M; Kanou T; Nakamura S
No To Shinkei; 1996 Aug; 48(8):719-25. PubMed ID: 8797205
[TBL] [Abstract][Full Text] [Related]
13. Correlation between histological grade and MIB-1 and p53 immunoreactivity in meningiomas.
Ozen O; Demirhan B; Altinörs N
Clin Neuropathol; 2005; 24(5):219-24. PubMed ID: 16167545
[TBL] [Abstract][Full Text] [Related]
14. Role of p53 gene mutation in tumor aggressiveness of intracranial meningiomas.
Cho H; Ha SY; Park SH; Park K; Chae YS
J Korean Med Sci; 1999 Apr; 14(2):199-205. PubMed ID: 10331568
[TBL] [Abstract][Full Text] [Related]
15. Pathological analyses of early recurrence and malignant transformation in meningiomas.
Arai H; Beppu T; Wada T; Yoshida Y; Kubo Y; Suzuki M; Ogawa A
Brain Tumor Pathol; 1998; 15(1):37-40. PubMed ID: 9879462
[TBL] [Abstract][Full Text] [Related]
16. Methylation of p14(ARF) gene in meningiomas and its correlation to the p53 expression and mutation.
Amatya VJ; Takeshima Y; Inai K
Mod Pathol; 2004 Jun; 17(6):705-10. PubMed ID: 15073599
[TBL] [Abstract][Full Text] [Related]
17. Assessment of candidate immunohistochemical prognostic markers of meningioma recurrence.
Csonka T; Murnyák B; Szepesi R; Bencze J; Bognár L; Klekner A; Hortobágyi T
Folia Neuropathol; 2016; 54(2):114-26. PubMed ID: 27543769
[TBL] [Abstract][Full Text] [Related]
18. Prognostic significance of Ki-67/MIB-1 proliferation index in meningiomas.
Torp SH; Lindboe CF; Grønberg BH; Lydersen S; Sundstrøm S
Clin Neuropathol; 2005; 24(4):170-4. PubMed ID: 16033133
[TBL] [Abstract][Full Text] [Related]
19. The significance of immunohistochemical expression of Ki-67, p53, p21, and p16 in meningiomas tissue arrays.
Terzi A; Saglam EA; Barak A; Soylemezoglu F
Pathol Res Pract; 2008; 204(5):305-14. PubMed ID: 18374497
[TBL] [Abstract][Full Text] [Related]
20. Malignant progression in meningioma: documentation of a series and analysis of cytogenetic findings.
Al-Mefty O; Kadri PA; Pravdenkova S; Sawyer JR; Stangeby C; Husain M
J Neurosurg; 2004 Aug; 101(2):210-8. PubMed ID: 15309910
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
